HUTCHMED

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regard

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

Monthly Return

Total Voting Rights

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

TR-1: Standard form for notification of major holdings

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

Interim Report 2024

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

Monthly Return

List of Directors and Their Roles and Functions

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Monthly Return

Overseas regulatory announcements: Filing of Form F-3

Blocklisting Six Monthly Return

Total Voting Rights

HUTCHMED to Announce 2024 Half-Year Financial Results

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

Monthly Return

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Total Voting Rights

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

List of Directors and Their Roles and Functions

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

List of Directors and Their Roles and Functions

Annual General Meeting held on May 10, 2024 – Poll Results

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees

Monthly Return

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Vesting of awards under the Long Term Incentive Plan

Annual General Meeting 2024

2023 Annual Report and Notice of Annual General Meeting

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Monthly Return

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Dissemination of Corporate Communications

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

Vesting of awards under the Long Term Incentive Plan

Monthly Return

Publication of Form 20-F

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session